Following Millennium Merger, Takeda's Hopes Dashed To Be Among Number Three In Japan

Takeda and Millennium's combined oncology unit has 13 molecules in clinical development, six of which are in Phase II or III, including potential first-in-class opportunities

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip